Hello, everyone, and nice to see you again after a brief sojourn in a foreign land, where we had a chance to hobnob with some interesting and well-informed people. Now, though, we have returned to the usual routine. Time does go quickly, yes? So once again, we are firing up the trusty coffee kettle for a cup of stimulation (maple pecan is truly delicious) and scavenging for items of interest. On that note, here are a few tidbits to get you going. Hope today is a productive one and you conquer the world.

Even as Purdue Pharma fights lawsuits accusing the company of using misleading tactics to promote highly addictive opioids, another company owned by the Sackler family has used the same tactics to peddle its signature painkiller, OxyContin, in China, the Associated Press reports. Mundipharma tells doctors that time-release painkillers like OxyContin are less addictive than other opioids — the same pitch that Purdue Pharma, the U.S. company owned by the family, admitted was false in court more than a decade ago.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy